CSL Canada Announces First Canadian Patient Receives HEMGENIX® Hemophilia B Gene Therapy in Ontario, Canada
Canada and CSL Seqirus, a Global Leader in Influenza Vaccines, agree on new Pandemic Preparedness Contract
Data Published in the New England Journal of Medicine Confirm the Long-term Durability and Safety of HEMGENIX® Over Five Years
CSL Honoured as Overall Winner of the 2025 Facility of the Year Awards by the International Society for Pharmaceutical Engineering
Recent RWE Data Show Cell-Based Influenza Vaccines Offer 20% Greater Protection in the Prevention of Test-Confirmed Influenza in Pediatric and Adult Populations Relative to Standard Egg-Based Influenza Vaccines
CSL Behring Signs Letter of Intent with pan-Canadian Pharmaceutical Alliance for Public Reimbursement of HEMGENIX® , the First Gene Therapy for Hemophilia B
CSL Vifor and Travere Therapeutics Recognize Updated KDIGO Clinical Practice Guidelines for IgA Nephropathy
Manhattan Uranium and Fortune Bay Commence Drilling at the Murmac Uranium Project, Athabasca Basin, Saskatchewan
Fortune Bay and Manhattan Uranium Commence Drilling at the Murmac Uranium Project, Athabasca Basin, Saskatchewan
